- CMS won't move ahead with some proposed Medicare drug plan changes
- CMS Medicare analysis found mail order more expensive than community pharmacy across 21 plans
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- CMS: Medicare Part D beneficiaries who hit 'doughnut hole' saved $8.9 billion in 2013 thanks to Affordable Care Act
WASHINGTON — The Internal Revenue Service has released its guidance on the healthcare-reform law’s tax on drug makers, according to documents posted on the agency’s website.
The tax applies to branded drug companies with total sales of at least $5 million to government health programs, including Medicare, Medicaid, Tricare and programs administered by the defense and veterans affairs departments.
The tax is expected to raise more than $2 billion per year, according to published reports. Drug companies have until Jan. 20 to obtain a fee calculation from the IRS, and until June 2 to offer comments.